Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects

NCT01405261 Phase 1 COMPLETED

This trial is conducted in Europe. The aim of this trial is to investigate safety, tolerability and pharmacokinetics (the exposure of the trial drug in the body) of single doses of NNC 0113-0987 in healthy male subjects.

Details

Lead sponsor	Novo Nordisk A/S
Phase	Phase 1
Status	COMPLETED
Enrolment	101
Start date	2011-08
Completion	2012-05

Conditions

• Diabetes
• Diabetes Mellitus, Type 2
• Healthy

Interventions

• oral NNC 0113-0987
• oral NNC 0113-0987
• I.v. NNC 0113-0987
• oral placebo

Primary outcomes

• Overview of Treatment Emergent Adverse Events (AEs) — Up to 25 days after trial product administration

Countries

United Kingdom